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Objectives: This study aimed to determine anti-coagulant treatment patterns and 
stroke- and bleeding-related risk factors and to evaluate quality of life (QoL) in non-
valvular atrial fibrillation (NVAF) patients. MethOds: This multicenter (12-centers), 
observational study included ≥ 18 year-old patients (n= 213) diagnosed with NVAF. 
CHADS2, CHA2DS2-VASc, HAS-BLED scores and EQ-5D scale were used to assess risk 
factors and QoL and clinical features were recorded at baseline, and 6th and 12th 
months. Results: The rate of adverse events was 64.7%, major bleeding was 10.8%, 
stroke was 5.9%, and hospitalization was 25.5% in one-year follow-up. The patients’ 
treatment patterns were grouped as warfarin, new oral anti-coagulant (NOAC) (dabi-
gatran, rivaroxaban), and antiplatelet agents (AA) (acetylsalicylic acid, clopidogrel). 
Patient numbers for the groups at baseline, and 6th and 12th months, respectively, 
were 92, 74, 41 for warfarin, 2, 13, 14 for NOAC, and 39, 29, 26 for AA. The distribution 
of patients in the warfarin, NOAC, and AA groups regarding CHADS2≥ 2 was 53.8% 
(n= 49), 50% (n= 1), and 63.2% (n= 24), respectively; regarding CHA2DS2-VASc≥ 2 was 
86.8% (n= 79), 50% (n= 1), and 89.5% (n= 34), respectively; and regarding HAS-BLED≥ 3 
(high bleeding risk) was 23.1% (n= 21), 0% (n= 0), and 18.4% (n= 7), respectively. EQ-5D 
scale scores were 0.85±0.12 and 0.76±0.13 at baseline and 0.67±0.29 and 0.62±0.37 at 
12th month for the warfarin and AA groups, respectively; the decrease was significant 
in the warfarin group (p= 0.002) but not in the AA group (p= 0.249). The mortality rates 
of the patients in the warfarin, NOAC, and AA groups in one-year follow-up were 7.6%, 
0.0%, and 10.3%, respectively. cOnclusiOns: Our study has demonstrated that a 
significant number of patients who should be on oral anticoagulants are still treated 
with AA and the negative effects of warfarin on QoL of NVAF patients as compared 
to AA. More data is needed with head-to-head comparison of warfarin and NOAC.
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Objectives: 2579 permanent cardiac pacemakers (PCPM) were implanted in 
Slovakia in the year 2012, 532 reimplantations were utilised in 475 resp. 98 per 
1000000 inhabitants. Up to now in the Slovak Republic there was not realised the 
study oriented on OoL in the patients with this treatment. MethOds: 100 patients 
with PCMK were studied, women 58, men 42. The average age was 66.47, duration of 
illness – 6.93 y. 57 patients were married, 31 divorced or a widower, widow, single - 
12.39 patients had sick sinus syndrome (SSS). 22 - AV blockade II, 23 - AV blockade III, 
16 - brady form of atrial fibrillation. QoL was evaluated by standardised instrument 
and so Quality of Life Index Cardiac Version – IV). Four domains were examined: 
health and functional state, mental and spiritual state, family relations. Finally, the 
total QoL was discovered, too. Kruskall Wallis Anova Test and Mann-Whitney Tests 
were used to verify the statistical significance. Results: None of rhythm disor-
ders and the duration of illness had impact on QoL. The smallest QoL occurred in 
health and functional state, the highest QoL occurred in family relations. In the last 
one (family relations) there was significant difference in comparison to the other 
domains (p ≤ 0,029), and specifically in the group of married patients. The age had 
negative significant correlation on QoL (p ≤ 0,027). Women had significant lower 
QoL in the social and economical fields. cOnclusiOns: PCPM has a certain impact 
on QoL. The knowledge about the differences in the field of family state and in age 
gives the incentive to take more attention to older, divorced, widower/widows and 
single patients and try to realise relevant psychological interventions.
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Objectives: The aim of the study was a subjective evaluation of the quality of life 
among adults with diagnosed and treated hypertension. The paper also identifies 
social and clinical factors significantly influencing the quality of life of respondents.  
MethOds: 112 people took part in the study (38 women and 78 men), aged between 19 
and 65 years old – in all cases hypertension was diagnosed and treated in a particular 
health care centre. As a main study tool a questionnaire WHOQOL-BREF in a Polish 
version was applied. In addition, in order to evaluate the social and clinical factors that 
influence the quality of life participants were asked to fill anonymous questionnaire 
prepared specially for this study. Results: The results of the conducted studies indi-
cated that people suffering from hypertension experience remarkably lower quality 
of life comparing to healthy people. Considerable discrepancies in terms of the qual-
ity of life were visible in physical and psychological domains of the WHOQOL-BREF 
questionnaire. It has been assumed that the quality of life of patients with hyper-
tension is determined by both social (age, gender, education, economic status), and 
clinical (level of blood pressure, weight, the type of hypertensive therapy, the presence 
of coexisting diseases). cOnclusiOns: Chronic diseases, including hypertension, 
distinctively affect the quality of life of patients. The quality of life of patients with 
hypertension is determined by numerous social and clinical factors. Thus, there is a 
need to consider the problem of hypertension and its treatment among adult people 
multidisciplinary – in order to improve their lives.
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lation-related PROs were identified: 1) Sawicki questionnaire (assesses treatment 
satisfaction and HRQOL); 2) Perception of Anticoagulant Treatment Questionnaire 
(PACT-Q); 3) Duke Anticoagulation Satisfaction Scale (DASS); 4) Anti-Clot Treatment 
Scale (ACTS) (based on the DASS conceptual model); and 5) Deep Venous Thrombosis 
Quality of Life (DVTQOL) (assesses HRQOL outcomes related to a primary event of 
DVT and includes items assessing anticoagulation burden). All of the measures 
except the Sawicki questionnaire involved anticoagulated patients in the process 
of item generation and refinement. The ACTS and the DASS exhibited the strongest 
measurement properties. To a limited degree, the ACTS, DASS, and Sawicki question-
naire have demonstrated responsiveness in clinical trial settings. cOnclusiOns: 
Although some of the identified measures have shown responsiveness in clinical 
trials, this review concluded that no existing measure appears likely to support an 
FDA or EMA PRO label claim in anticoagulation-related treatment satisfaction or 
HRQOL. However, concepts related to anticoagulation treatment satisfaction and 
HRQOL are important to patients and should be included in clinical trials, particu-
larly as the burdens and benefits of anticoagulants evolve over time.
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Objectives: To compare the health utility of Acute Coronary Syndrome (ACS) 
patients from an Asian population at baseline admission and 12 months post-ACS. 
Secondary objectives were to investigate the factors that affect health utility and 
the impact of using local versus UK tariffs in the analysis. MethOds: Primary 
data was obtained from ACS patients who were admitted to a tertiary-care, general 
hospital in Malaysia and agreed to participate in the study. The quality of life (QOL) 
of ACS patients was elicited using validated language versions of the EQ-5D (three 
severity level) patient reported outcome instrument. QOL data was collected at 
baseline during initial admission for ACS and at 12-months post-admission. Patient 
demographic and clinical data were extracted from medical records. Health utility 
scores were calculated using EQ-5D utility tariffs from Malaysia and the UK popula-
tion tariff. Results: A total of 112 subjects were recruited into the study of which 
104 were used in the primary analysis. Mean age of patients in the analysis dataset 
was 56.1 years, 88% were male and duration of admission was 6.3 days. Calculated 
by Malaysian tariff weights, health utility was 0.75 during initial admission, increas-
ing to 0.82 after 12 months (p= 0.012). Among the statistically significant factors 
associated with lower baseline utility were diagnosis of NSTEMI/unstable angina 
compared to STEMI (p= 0.045), and female sex (p= 0.038). Utilities calculated using the 
Malaysian tariff was consistently higher than those calculated using the UK tariff. 
ACS utility at baseline was 0.75 and 0.62 (p< 0.001) while utility after 12 months was 
0.82 and 0.72 (p< 0.001) respectively. cOnclusiOns: This study investigates several 
factors that may impact the QOL outcomes of Malaysian ACS patients. It also found 
significant differences in utility values calculated by Malaysian and UK tariffs, which 
indicate that the use of local tariffs is more appropriate.
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Objectives: A secondary objective of a phase-III study spanning 54 weeks was to 
measure changes in the health-related quality of life (HRQoL) of 2,690 patients ≥ 18 
years of age with moderate-to-severe hypertension who ended up receiving one of 
six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) using the 
MINICHAL and EQ5D instruments. MethOds: Descriptive statistics were used to 
measure blood pressure and HRQoL scores over the study period. Analysis of covari-
ance (ANCOVA) was used to identify those factors (i.e. age, sex etc.) that could pos-
sibly have influenced HRQoL. Linear regression was used to assess the relationship 
between changes in blood pressure and HRQoL scores. Results: At the study start 
90.8% of patients had Grade 2 or 3 hypertension, but at the study end 91.9% had nor-
mal/high-normal BP. Patients’ baseline MINICHAL mood and somatic domains scores 
were 5.5 and 2.6. Over the study period HRQoL improved as both MINICHAL scores 
decreased by 31-33%. Patients’ baseline EQ5D index and VAS score was 0.9 and 73.4 
respectively, increasing by 6% and 12% over the study period. Patients’ QALY gain over 
the 54 weeks study period was estimated to be 0.029 QALYs. Linear regression was 
unable to detect any correlation between the changes in blood pressure and HRQoL 
scores. The ANCOVA model showed that changes in patients’ HRQoL was likely to 
have been influenced by patients’ grade of hypertension at baseline, the amount of 
concomitant medication (“pill burden”) and patients’ antihypertensive treatment in 
the last 26 weeks of the study. cOnclusiOns: OLM/AML/HCTZ reduced blood pres-
sure and significantly increased blood pressure control whilst improving patients’ 
HRQoL. Reducing patients’ pill burden is likely to increase adherence to treatment 
and improve blood pressure control. Hence, when prescribing antihypertensive agents 
physicians should consider the impact that pill burden has on adherence to treat-
ment, achieving blood pressure control and patients’ HRQoL.
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tings. Descriptive statistics were used to look at items of interest. Results: There 
were 1403 discharges meeting the inclusion criterion. These were linked to 1402 ER 
discharges previous to the surgery. There were no significant differences between 
the genders in terms of characteristics like race, primary payer, age, etc. However, 
more men had ER visits than women (52.43% vs 47.57%). The top diagnosis in the 
ER consisted of conduction disorders (21.03%). Syncope occurred in 10.05% of dis-
charges. Atrial fibrillation was the only ER diagnosis which women experienced 
more than men. cOnclusiOns: The findings of the study were inconclusive in 
showing significant differences between the genders in terms of characteristics 
and ER diagnosis among recipients of primary pacemaker.
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Objectives: To estimate low-density lipoprotein cholesterol (LDL-C) goal attainment 
in patients with hyperlipidemia or prior cardiovascular (CV) events. MethOds: 
Retrospective population-based cohort study conducted using electronic medical 
records linked to national registers. Patients were included in the study based on a 
prescription of lipid-lowering treatment between January 1, 2006 and December 31, 
2006 or history of CV events (prior to 2006) and followed until December 31, 2012 for 
estimation of LDL-C goal attainment. Patients were stratified into cohorts based on 
CV risk level. Propensity score matching was applied to compare patients with new 
events (myocardial infarction, unstable angina, revascularization, ischemic stroke, 
transient ischemic attack or heart failure) to patients without new events. Results: 
Mean LDL-C at the time of the new CV event (index date) was 100.4 mg/dL for 
patients with CV event history who had a new event (n= 1,101). The mean LDL-C 
for patients without new events in the same cohort (n= 1,304) was 97.4 mg/dL. The 
proportion of patients with CV event history and LDL-C < 70 mg/dL was 20.5% and 
21.5% for patients with and without new events, respectively. The percentage who 
attained the goal of 100 mg/dL was 54.1% and 58.1%, respectively. Mean LDL-C for 
CV risk equivalent (RE) patients with new events (n= 803) was 100.3 mg/dL while 
patients in the same cohort without new events (n= 975) had a mean level of 97.4 mg/
dL. 22.0% of CV RE patients with new events had a LDL-C < 70 mg/dL and 53.8% had 
a level < 100 mg/dL. The corresponding data for CV RE patients without new events 
were 19.1% and 57.7%, respectively. cOnclusiOns: The proportion of patients who 
met LDL-C goals was low, suggesting that current treatment is suboptimal. The pro-
portion of patients who attained the goals was similar in patients with and without 
new events and across CV risk levels.
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Objectives: To estimate the clinical impact over three years of switching atrial 
fibrillation (AF) patients receiving no treatment or aspirin, or Vitamin K antago-
nist (VKA), to rivaroxaban in China. MethOds: A prevalence-based, deterministic 
budget impact model was developed. The number of AF patients was calculated 
based on data from literatures. The baseline risk of events and the efficacy and 
safety data for aspirin and VKA were from meta-analysis. While the efficacy and 
safety data for rivaroxaban were from ROCKET-AF trial. The current treatment pat-
tern was from a large registry study for Chinese AF patients. 9%, 61% and 30% of AF 
patients received no treatment, aspirin and VKA, respectively. We just assumed that 
5% of the patients who received aspirin currently switch to rivaroxaban per year. 
Then the model estimates the number of ischemic stroke (IS), systemic embolisms 
(SE), myocardial infarction (MI), intracranial bleeds (ICH) and major extracranial 
bleeds (ECH) per year. Results: The number of NVAF patients is 4.5 million. For 
those patients, there might be 127,469 major IS events, 34,001 SE events, 9,933 MI 
events, 28,745 ICH events and 56,193 major ECH events under current treatment 
per year. With 5% patients switching to rivaroxaban from aspirin in the first year, 
the IS events reduced 4%, SE events reduced 6% and MI events reduced 2% with 
increased 3% ICH and 1% ECH. To the third year, the IS events continue to reduce 
11%, SE events reduced 17% and MI events reduced 6% with increased 10% ICH and 
4% ECH compared with the current situation. cOnclusiOns: Rivaroxaban may 
decrease the clinical burden of AF in China by reducing the incidence of stroke and 
fatal CV events. Decision-makers can find the exact value of rivaroxaban easily by 
the simple tool in different situations.
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Objectives: To estimate the clinical impact over three years of switching deep 
vein thrombosis (DVT) patients receiving low molecular weight heparin (LMWH) 
and vitamin K antagonist (VKA) to rivaroxaban. MethOds: A prevalence-based, 
deterministic budget impact model was developed. The incidence of DVT patient 
was from literatures. We assumed that 12%, 65% and 23% received treatment for 
3months, 6months and 12months, separately. The efficacy and safety data for 
LMWH+VKA were from meta-analysis. While the efficacy and safety data for rivar-
oxaban were from EINSTEIN-DVT trial. We just assumed that 20% of the patients 
who received LMWH + VKA currently switch to rivaroxaban in the first year and 
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Objectives: Following an acute deep vein thrombosis (DVT) or pulmonary 
embolism (PE) event, physicians can choose among heparin, vitamin K antago-
nists (VKA), and Non-VKA oral anticoagulants (NOAC) for therapy. We assessed 
patients’ satisfaction with their ongoing anticoagulation treatment. MethOds: 
PREFER in VTE (PREvention oF thromboembolic events – European Registry in 
Venous Thromboembolism) is an ongoing non-interventional study in France, 
Germany, Austria, Switzerland, Italy, Spain and UK. The Perception of Anti-Coagulant 
Treatment Questionnaire (PACT-Q2) is a valid and reliable instrument that allows 
the assessment of patients’ satisfaction regarding anticoagulant treatment, as well 
as their opinion about convenience of use. Results: At baseline (BL), a total of 
2311 patients with acute VTE (1366 DVT, 945 PE) met the eligibility criterion of cur-
rent anticoagulation and completed the PACT-Q2 questionnaire. 665 patients were 
eligible for an interim analysis at 6 months: 7.8% have received heparin only, 33.2% 
initial heparin/VKA and 9.0% uninterrupted NOAC. In the “convenience” dimen-
sion, the score (0-100 range) at BL/6 months was 78.9 ±17.62/ 76.2 ±18.20 points for 
heparin only, 81.0 ±16.36/ 80.5 ±16.34 for heparin/VKA, and 88.9 ±12.14/ 93.3 ±7.30 for 
NOACs (all patients: 81.5 ±16.78/ 81.6 ±17.26). Compared to BL, the score improved 
the most in the NOAC group. In the “anticoagulant treatment satisfaction” dimen-
sion, the score at BL/ 6- month was 64.2 ±14.02/64.3 ±16.68 points for heparin only, 
65.8 ±14.92/68.7 ±14.46 for heparin/VKA and 68.2 ±16.65/72.9 ±16.70 for NOACs (all 
patients 65.4 ±15.26/68.5 ±15.76). cOnclusiOns: Overall, patients on current anti-
coagulation reached relatively high values on the convenience scale, but moderate 
values on the satisfaction scale. Patients on NOACs rated their convenience and 
treatment satisfaction substantially higher than patients on heparin/VKA.
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Objectives: We aimed to understand treatment satisfaction over time under eve-
ryday practice conditions after introduction of NOACs (Non vitamin K antagonist 
oral anticoagulants) in the The PREvention oF thromboembolic events – European 
Registry in Atrial Fibrillation (PREFER in AF). MethOds: PREFER in AF documents 
clinical characteristics, management, quality of life and other outcome parameters 
of AF patients. A total of 6412 consecutive patients with ECG-confirmed AF in the 
previous 12 months were followed up prospectively. The ‘Perception of Anticoagulant 
Treatment Questionnaire’ is a valid and reliable instrument to assess patients’ 
expectations (PACT-Q1) and satisfaction regarding anticoagulant treatment, as 
well as patients’ opinion about treatment convenience of use (PACT-Q2). Results: 
A total of 2985 patients were willing to fill out the PACT-Q2 questionnaire both at 
baseline and FU. 1632 of these were on vitamin K antagonists (VKAs), 374 on NOACs, 
203 on antiplatelets (AP), 142 on VKA+AP combinations and 634 on neither treat-
ment. In the “convenience” dimension, the overall score (0-100 range) at FU was 
84.3 ±16.5. The scores ranged from 81.9 in the no NOAC/VKA/AP group (± 18.43), 
84.0 AP (± 16.7), 84.4 NOAC (± 15.9), 85.0 VKA (± 15.9) to 86.8 in the VKA +AP group 
(± 14.13). In the “anticoagulant treatment satisfaction” dimension of the PACT-Q2, 
the overall score was 65.1 ±15.7. The scores ranged from 64.5 in no NOAC/VKA/AP 
(± 14.8), 63.2 in AP group (± 17), 66.0 in NOAC (± 15.05), 64.9 in VKA (± 15.9), to 69.5 in 
VKA +AP group (± 15.8). cOnclusiOns: Overall, patients on current anticoagulation 
achieve relatively high values on the convenience scale, but moderate values on the 
satisfaction scale. While differences in group size and patient characteristics need to 
be taken into account, patients on NOACs compared to patients on VKAs rate their 
convenience and treatment comparable to other treatment schemes.
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Objectives: Men’s and Women’s health care experiences differ as they age. These 
differences lead to disparate health and treatment outcomes between the genders, 
especially in the area of cardiac health, which has significant disease burden in 
the US. Women experience symptoms that ‘deviate’ from the ones found in a clini-
cian’s guidebook. The emergency room (ER) also serves as a medical space for initial 
diagnosis of heart conditions. Thus, looking at the gender based use of ER prior to 
a cardiac event may help us understand the disparities from a systems perspec-
tive. Cardiac pacemakers are used to treat severe and/or symptomatic bradycardia, 
heart block or a combination of both. This study explored gender differences in 
characteristics and ER diagnoses associated with pacemaker implants in an inpa-
tient setting. MethOds: The study used data from the inpatient and emergency 
room hospital discharge data from the Florida HealthCare Utilization Project for 
years 2009 and 2010. Patients with a primary insertion of initial pacemaker and 
with a diagnosis of bradycardia or heart block or both were included. A unique 
patient identifier helped map patients across the inpatient and emergency set-
